Experimental Dermatology · 2013 · 37 citations · 24 references
Life SciencesDermatologyPathologyAutoimmunityCell SignalingSignal TransductionAutoimmune Blistering DiseasesAutoimmune Skin DiseasesCell-surface ReceptorsEpidermal TissueImmunopathology Of SkinSkin TumorsAutoimmune Blistering DermatosesAutoimmune Skin Blistering DisordersCutaneous BlisteringEgfr InhibitionEpidermal Cell SignalingErlotinib TherapyImmunosuppressive Drug TherapySubepidermal Blistering Disorders
Novel insights into intra-cellular signalling involved in pemphigus vulgaris (PV), an autoimmune blistering disease of skin and mucous membranes, are now revealing new therapeutic approaches such as the chemical inhibition of PV-associated signals in conjunction with standard immunosuppressive therapy. However, extensive inhibition of signalling molecules that are required for normal tissue function and integrity may hamper this approach. Using a neonatal PV mouse model, we demonstrate that epidermal blistering can be prevented in a dose-dependent manner by clinically approved EGFR inhibitors erlotinib and lapatinib, but only up to approximately 50% of normal EGFR activity. At lower EGFR activity, blisters again aggravated and were highly exacerbated in mice with a conditional deletion of EGFR. Statistical analysis of the relation between EGFR activity and the extent of skin blistering revealed the best fit with a non-linear, V-shaped curve with a median break point at 52% EGFR activity (P = 0.0005). Moreover, lapatinib (a dual EGFR/ErbB2 inhibitor) but not erlotinib significantly reduced blistering in the oral cavity, suggesting that signalling mechanisms differ between PV predilection sites. Our results demonstrate that future clinical trials evaluating EGFR/ErbB2 inhibitors in PV patients must select treatment doses that retain a specific level of signal molecule activity. These findings may also be of relevance for cancer patients treated with EGFR inhibitors, for whom skin lesions due to extensive EGFR inhibition represent a major threat.
24
R: A Language and Environment for Statistical Computing
R Core Team · 2000 · 353K citations · Full text
Natural Sciences, Computer Science, Statistical Computing +10
Estimating regression models with unknown break‐points
Vito M. R. Muggeo · Statistics in Medicine · 2003 · 2.3K citations
Ken Ishii, Masayuki Amagai, Russell P. Hall et al. · The Journal of Immunology · 1997 · 481 citations · Full text